 The FDA has accepted for review Incyte Corporations NASDAQ: INCY marketing application for parsaclisib for relapsed or refractory follicular lymphoma FL, marginal zone lymphoma MZL, and mantle cell lymphoma MCL. Parsaclisib is an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta PI3Kδ. 